Immunogenicity of Novel H1N1 Vaccination Among HIV-Infected Compared to HIV-Uninfected Persons
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00996970
Recruitment Status : Unknown
Verified October 2018 by Timothy Burgess, MD, MPH, Uniformed Services University of the Health Sciences. Recruitment status was: Active, not recruiting
First Posted : October 16, 2009
Last Update Posted : October 11, 2018
Uniformed Services University of the Health Sciences
Infectious Diseases Clinical Research Program
National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by (Responsible Party):
Timothy Burgess, MD, MPH, Uniformed Services University of the Health Sciences
The purpose of this research is to determine the effectiveness of the novel H1Nl influenza (inactivated/killed formulation) vaccine among both HIV-infected and HIV-uninfected persons. The administration of the H1Nl vaccination is not part of the study's procedures, but is being given as part of routine care.
Condition or disease
The investigators study is being conducted to evaluate and compare the seroresponses of the novel H1N1 vaccination among HIV positive and negative persons receiving the novel H1N1 vaccination as part of routine clinical care, with secondary objectives examining the impact of prior seasonal vaccinations on subsequent seroresponse to the novel H1N1 vaccination, determining potential reactions (local or systemic) to this new vaccine among patients, and assessing for potential immunologic/virologic changes (in CD4/HIV RNA levels) after H1N1 vaccination among HIV patients. Finally, the investigators will collect data on influenza-like illnesses (ILI) and H1N1 events during the study follow-up period and influenza isolates causing ILI events will be genetically characterized.
To compare the immunogenicity via anti-hemagglutinin responses following H1N1 vaccination between HIV positive and negative persons. [ Time Frame: interim = 2 months; 6 month f/u = 8 months ]
Secondary Outcome Measures :
To compare the immunogenicity via HAI titer levels, microneutralization seroresponses and titer levels, and cellular responses following H1N1 vaccination between HIV positive and negative persons. [ Time Frame: 1 year ]
Among those undergoing vaccination with the seasonal influenza vaccine during the current influenza season, to compare the presence of a positive seroresponse between HIV positive and negative persons [ Time Frame: 1 year ]
To evaluate the effect of pre-existing anti-influenza immunity and recent history of seasonal influenza vaccination on seroresponses to the H1N1 influenza vaccine among both HIV positive and negative persons. [ Time Frame: 1 year ]
To compare the durability of the H1N1 immunologic responses at 6 months post-vaccination between HIV-infected and uninfected persons. [ Time Frame: 1 year ]
To evaluate the number of ILIs and documented influenza cases among HIV-infected and uninfected persons after initial vaccination, and to genetically characterize the influenza strains causing ILI events in our study cohort. [ Time Frame: 1 year ]
To evaluate the impact of CD4 counts/percentages, HIV RNA levels, and HAART use on the immunologic responses to H1N1 vaccination in HIV positive subjects. [ Time Frame: 1 year ]
To evaluate the impact of the H1N1 vaccine on CD4 counts/percentages and HIV RNA levels in HIV positive subjects. [ Time Frame: 2 months ]
To evaluate potential adverse reactions of the H1N1 vaccine in HIV positive versus negative subjects. [ Time Frame: 2 months ]
Biospecimen Retention: Samples Without DNA
Blood samples will be collected for immunologic studies including antibody titers and cellular responses. Viral isolates will be obtained and characterized among ILI cases during study participation. Blood for CD4/HIV RNA levels will also be obtained among HIV patients to determine the impact of the vaccine on these counts.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 50 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Males and females of all races and all military beneficiaries including active duty enlisted and officers (from all branches of service), retirees, and their dependents presenting for H1N1 vaccination as part of routine clinical care will be eligible for participation. Both HIV-positive and negative persons can participate. Since most of our HIV patients are 18-50 years of age, and seroresponse varies by age, we will enroll persons between the ages of 18-50 years.
18-50 years of age
Receiving the novel H1N1 vaccine (killed formulation) as part of routine clinical care
A military beneficiary who expects to remain in the local area for the next 6 months
Healthcare worker who is involved in direct patient care
Acute febrile illnesses within 30 days prior to H1N1 vaccination (e.g., pneumonia, influenza, ILI)
Diabetes type 1 or type 2
Systemic steroid or immunosuppressive medication use within 4 weeks of vaccination
Active diagnoses of a cancer (non-melanoma skin cancer allowed).
History of organ transplant
Chronic active hepatitis B or C
Active illicit drug use or alcohol abuse
Blood transfusion within the last year
Allergy to eggs
Previous significant adverse reaction (e.g., anaphylaxis) to the seasonal influenza vaccination
History of serious reactions to any prior vaccination (e.g., Guillain Barre Syndrome (GBS)).
Received another vaccination in the last 4 weeks (receipt of seasonal influenza vaccination is allowed)
Among females of childbearing potential, pregnant or within 6 weeks of being postpartum
History of ILI which was confirmed as an H1N1 infection